
10/13/04 WED 15:19 FAX

RAW SEQUENCE LIST MG ERROR REPORT



FECEIVED

DEC 2 1 2001

GIECH CENTER 1600/2900

The Biotechnology Systems Branc and the Scientific and Technical Information Center (STIC) detected errors who a processing the following computer readable form:

Application Serial Number: 09/134,583

Source: \_\_\_\_C

Date Processed by STIC:

9/6/2001

C/O ALLAN

FENUCCI

THE ATTACHED PRINTOUT EXPLA INSIDET ECTED ERRORS.

PLEASE FORWARD THIS INFORMA IDN TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PIRITOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE T I XIMILY or,

2) TELEPHONING APPLICANT AN INAXING A COPY OF THIS PRINTOUT, WITH A 3306 1266 NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS FLEASE CONTACT MARK SPENCER, 703-308-4212.

mark, spenier D

FOR SEQUENCE RULES INTERPRINATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin211 | 100 200 | pto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3ht p@us) to.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUE (CF. LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACC. SS. BI E THROUGH THE U.S. PATENT AND

TRADEMARK OFFICE WEBSITI SEE BELOW:

#### Check or Version 3.0

The Checker Version 3.0 application is a stre-of the art Windows based software program employing a logical and intuitive user-intersing the concentration of a logical and intuitive users in the concentration of a logical and intuitive users in the concentration of a logical property Organization (WIPO) Standard Single Concentration of Checker and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker, and its Y2K-compliant. Checker allows public users to concentration of Checker and the concentrati

Onecker Version 3.0 can be down loaded | registhe USPTO website at the following address:

http://www.uspto.fp/web/offices/pac/checker

#### Raw Sequence Listing Error Summary

	00/00// 022
ERROR DETECTED	SUGGEST 12 STRE ICTION SERIAL NUMBER: 09/734, 583
ATTN: NEW RULES CASE	: Please in  re( ar) english "alpha" headers, which were inserted by  pto soft/vari
1Wrapped Nucleics Wrapped Aminos	The number out at the sid of each line "wrapped" down to the next line. This may occur if your file was retrieve in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wn :p ng"
2Invalid Line Length	The rules ro like that a line not exceed 72 characters in length. This includes white spaces.
3Missligned Amino Numbering	The number 1g unfer each 5th amino acid is misaligned. Do not use tab codes between numbers; use space of 1 meet era, instead.
4Non-ASCII	The submitt : Hile was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your number que it submission is saved in ASCII text.
SVariable Length.	Sequence(s) 2e nital a n's or Xaa's representing more than one residue. Per Sequence Rules, each n or X = 121 only represent a single residue. Please present the maximum number of each residue havi   3 /aruble length and indicate in the <220> <223> section that some may be missing.
6Patestin 2.0 "bug"	A "bug" in I :: enth; version 2.0 has caused the <220><223> section to be missing from amino acid sequences (a
7Skipped Sequences (OLD RULES)	Sequence(a)mit sing. If intentional, please insert the following lines for each skipped sequence:  (2) DNFOIU A THIN FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  (i) EQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  (vi) SEQUII (d.E. DES: RIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  This sequent is a litent onally skipped
	Please also lijust the "(ii) NUMBER OF SEQUENCES:" response to Include the skipped sequences.
8Skipped Sequences' (NEW RULES)	Sequence(s missing. If intentional, please insort the following lines for each skipped sequence.  <210> pequates it muster  <400> sequates it not ther  000
9Use of n's or Xaa's (NEW RULES)	Use of n'ii i id or Xaa's have been detected in the Sequence Listing.  Per 1.223 o Siquimee Rules, use of <220>-<223> is: MANDATORY if n's or Xaa's are present.  In <220> (c -723 > section, please explain location of n or Xaa; and which residue n or Xaa represents.
10Invalid <213>	Per 1.823 o Siquence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific'n in ((unu hyacies), <220>-<223> section is required when <213> response is Unknown or is Artificial is juincy,
11Use of <220>.	Sequence(a missing the 4220> "Feature" and associated numerite identifiers and responses.  Use of <2:10 13
12Patentin 2.0 "bug"	Please do r :: 1 se "Copy to Disk" function of Patentla version 2.0. This causes a corrupted file, resulting in raising mindatory numeric identifiers and responses (as indicated on raw sequence listing). In .:: d, shear a use "File Manager" or any other manual means to copy file to floppy disk.
13Misuse of n	in can only in use i to represent a single nucleotide in a nucleic sold sequence. N is not used to represent any value and the afficility a nucleotide.

AN [C/MH - Biotechnology Systems Branch - 08/21/200]

Page 1 of 8

```
OIPE
                                                            DATE: 09/06/2001
                    RAW SEQUENCE LO SELING
                                                            TIME: 15:09:42
                    PATENT APPLICATION: US/09/734,583
                                                                       Does Not Comply
                    Input Set : A:\B'534-3000.txt
                                                                   Corrected Diskette Needeg
                    Output Set: N:\: 3UF3\(.9062001\I734583.raw
     3 <110> APPLICANT: Hornik, Ve: ad
     5 <120> TITLE OF INVENTION: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN
ANALOGS
     7 <130> FILE REFERENCE: 87534 3000
     9 <140> CURRENT APPLICATION N MEER: 09/734,583
     10 <141> CURRENT FILING DATE: DOC-12-13
     12 <160> NUMBER OF SEQ ID NOS: 1)
     14 <170> SOFTWARE: PatentIn ve sicn 3.1
     16 <210> SEQ ID NO:-1
     17 <211> LENGTH: 14
     18 <212> TYPE: PRT
     19 <213> ORGANISM: mammalian
     21 <400> SEQUENCE: 1
     Ala Gly Cys Lys Asn Phe Pha Try Lys Thr Phe Thr Ser Cys
        210> SEQ ID NO: 2 mal
                                                 see iteme 10 and 11 on Evin furnary
     28 <211> LENGTH: 6
     29 <212> TYPE: PRT
  30 <213> ORGANISM: Artificial epuids
     32 <220> FEATURE:
W--> 33 <221> NAME/KEY: DISULFIDE E IDGE
     34 <222> LOCATION: (1)..(1)
        COTHER INFORMATION: Consider at amino acid positions and 6 form a disulfide
birdg
     39 <220> FEATURE:
     40 <221> NAME/KEY: MOD_RES
     41 <222> LOCATION: (3)..(3)
     42 <223> OTHER INFORMATION: Transpression is the D isomer
     45 <400> SEQUENCE: 2
     47 Cys Phe Trp Lys Thr Cys
     48
     51(<210> SEQ ID NO:
     52 ₹211> LENGTH: 6
     53 <212> TYPE: PRT
C--> 54 <213> ORGANISM( Artificial poptice
     56 <220> FEATURE:
     57 <221> NAME/KEY: MOD_RES
     58 <222> LOCATION: (1)..(1)
    59 <223> OTHER INFORMATION: No Mosthy.
     62 <220> FEATURE:
     63 <221> NAME/KEY: MOD_RES
     64 <222> LOCATION: (1)..(6)
     65 <223> OTHER INFORMATION: COLC
     68 <220> FEATURE:
     69 <221> NAME/KEY: MOD_RES
     70 <222> LOCATION: (3)..(3)
     71 <223> OTHER INFORMATION: T a Trp residue is the D isomer
```

74 <400> SEQUENCE: 3

Page 2 of 8

RAW SEQUENCE LI TING

PATENT APPLICATION US/09/734,583

Page 3 of 8

DATE: 09/06/2001

TIME: 15:09:42

```
Input Set : A:\:7534-3000.txt
                     Output Set: N:\ FF3\09062001\1734583.raw
    76 Ala Tyr Trp Lys Val Phe.
    77 1
     80 <210> SEQ ID NO: 4
     81 <211> LENGTH: 8
     82 <212> TYPE: PRT
C--> 83 <213> ORGANISM: (Artificial lightide
     85 <220> FEATURE:
     86 <221> NAME/KEY: MOD_RES
     87 <222> LOCATION: (1)...(1)
     88 <223> OTHER INFORMATION: The Phe Residue is a D isomer
     91 <220> FEATURE:
     92 <221> NAME/KEY: MOD_RES
     93 <222> LOCATION: (8)..(8)
     94 <223> OTHER INFORMATION: The Fir residue ends with CH2OM
     97 <220> FEATURE:
                                                    bridge
W--> 98 <221> NAME/KEY: DISULFIDE B INCE
     100 <223> OTHER INFORMATION: A disulfide (bride) is formed between Cys residues 2 and 7
     103 <220> FEATURE:
     104 <221> NAME/KEY: MOD_RBS
105 <222> LOCATION: (2)...(2)
106 <223> OTHER INFORMATION: I set presidue is a D isomer
     109 <400> SEQUENCE: 4
     111 Phe Cys Phe Trp Lys Thr Cy: Thr
      112 1 '
      115 <210> SEQ ID NO: 5
      116 <211> LENGTH: 7
                                                  ) Arthicral Sequence.
      117 <212> TYPE: PRT
C--> 118 <213> ORGANISM: (Artificial l'eptide
      120 <220> FEATURE:
W--> 121 <221> NAME/KEY: DISULFIDE
      122 <222> LOCATION: (2)..(2)
                                      Diquifide Bridge is formed between the Cys residues at
      123 <223> OTHER INFORMATION: 1 DI
SYNTHETIC
position
                2 and 6
      124
      127 <220> FEATURE:
      128 <221> NAME/KEY: MOD_RES
      129 <222> LOCATION: (1)..(1)
      130 <223> OTHER INFORMATION: as Ph. residue is a D isomer
      133 <220> FEATURE:
      134 <221> NAME/KEY: MOD_RES
      135 <222> LOCATION: (4) ...(4)
      136 <223> OTHER INFORMATION: 'he Tro residue is a D isomer
      139 <220> FEATURE:
                                             residue
      140 <221> NAME/KEY: MOD_RES
      141 <222> LOCATION: (7)..(7)
      142 <223> OTHER INFORMATION: the Thr (reside) ends with N2H
      145 <400> SEQUENCE: 5
      147 Phe Cys Phe Trp Lys Cys T :x
                       5
      148 1
```

ا 196 م در این ناسمی

file://C:\Crf3\Outhold\VsrI734583.htm

Page 4 of 8

```
DATE: 09/06/2001
                     RAW SEQUENCE LED TEING
                                                             TIME: 15:09:42
                     PATENT APPLICAT 01: 1/8/09/734,583
                     Input Set : A:\ 7534-3000.txt
                     Output Set: N:\ RF2\0)062001\I734583.raw
    151 <210> SEQ ID NO: 6
     152 <211> LENGTH: 8
     153 <212> TYPE: PRT
C--> 154 <213> ORGANISM: Artificial eptids
     156 <220> FEATURE:
     157 <221> NAME/KEY: MISC_FEATUR:
     158 <222> LOCATION: (1)..(1)
     159 <223> OTHER INFORMATION: is a samma amino butyric acid, diamino butyric acid,
                  5-amino pentanoic ciri cr amino hexanoic acid; Residue 1 is (bi)
beta-Al
     160
              rdged to Residue 8; Fasidue 1 also begins with a hydrogen, or a n
     161
               ono- or di- saccharic a attached
     162
     165 <220> FEATURE:
     166 <221> NAME/KEY: MISC_FEATULE:
     167 <222> LOCATION: (2)..(2)
     168 <223> OTHER INFORMATION: i.: (D) or (L) Phe or Tyr
     171 <220> FEATURE:
     172 <221> NAME/KEY: MISC_FEATULE
     174 <223> OTHER INFORMATION: i. (C) or (L)-Trp, or (L)-Phe, (D)- or (L)-INal or (D) or
     173 <222> LOCATION: (3)..(3)
 (L)-2Na
               1, or Tyr
     175
      178 <220> FEATURE:
      179 <221> NAME/KEY: MISC_FEATU E
      180 <222> LOCATION: (4)..(4)
      181 <223> OTHER INFORMATION: i (I) or (L)-Trp
      184 <220> FEATURE:
      185 <221> NAME/KEY: MISC_FEATU E
      186 <222> LOCATION: (5)..(5)
      187 <223> OTHER INFORMATION: i \in \{D\} or \{L\}-Lys
      190 <220> FEATURE:
      191 <221> NAME/KEY: MISC_FEATURE
      192 <222> LOCATION: (6)..(6)
      193 <223> OTHER INFORMATION: is Tir, Gly, Abu, Ser, Cys, Val, (D) or (L)-Ala, or (D) - or
 (L)-A
      194
                la, or Tyr
      197 <220> FEATURE:
      198 <221> NAME/KEY: MISC_FEATURE
      199 <222> LOCATION: (7)..(7)
      200 <223> OTHER INFORMATION: :: (D) or (L)-Phe, or (D)- or (L)-Ala, Nle, or Cys;
      203 <220> FEATURE:
      204 <221> NAME/KEY: MISC_FEACH RE
      205 <222> LOCATION: (8)..(8)
      206 <223> OTHER INFORMATION: s Cly Val, Leu, (D) or (L)-Phe, or 1Nal or 2Nal; with a
 termina
                l carboxy acid, ami e cr alcohol group.
      207
                               ۲,
      210 <400> SEQUENCE; 6
 W--> 212 Xaa Xaa Xaa Xaa Xaa Xaa X a ) Aa
      213 1
      216 <210> SEQ ID NO: 7
      217 <211> LENGTH: 7
      218 <212> TYPE: PRT
 C--> 219 <213> ORGANISM Artificia Poptide
                                                                                             9/6/01
```

RAW SEQUENCE IN HILLING

Page 5 of 8

. DATE: 09/06/2001

```
PATENT APPLICATION: US/09/734,583
                                                              TIME: 15:09:42
                     Input Set : A:\B"534-3000.txt
                     Output Set: N:\ 3 [9062001 ] 1734583.raw
     221 <220> FEATURE:
     222 <221> NAME/KEY: MISC_FEATULE
     223 <222> LOCATION: (1)..(1)
     224 <223> OTHER INFORMATION: i. (D) - or (L)-Phe, or (D) - or (L)-Ala; wherein Residue 1 is
brid
               ged to Residue 6 a b: .dging group composed of 1 to 5 methyl space
     225
               rs connected to an article, thioether, thioester, or disulfide, fol
     226
               lowed by 1 to 5 meth 1 spacers
     227
     230 <220> FEATURE:
     231 <221> NAME/KEY: MISC_FEATURE _-
     232 <222> LOCATION: (2)..(2)
     233 <223> OTHER INFORMATION: i. Tyr or (D)- or (L)-Phe
     236 <220> FEATURE:
     237 <221> NAME/KEY: MISC_FEATURE
     238 <222> LOCATION: (3)..(3)
     239 <223> OTHER INFORMATION: \pm (L) - or (L)-Trp, (D) - or (L)-1Nal, or (D) - or (L)-2Nal
     242 <220> FEATURE:
     243 <221> NAME/KEY: MISC_FEATU E
     244 <222> LOCATION: (5)..(5)
     245 <223> OTHER INFORMATION: i Fir, Val, Ser, or Cys
     248 <220> FEATURE:
     249 <221> NAME/KEY: MISC_FEATU E
     250 <222> LOCATION: (6)..(6)
     251 <223> OTHER INFORMATION: i 31y or (D) - or (L)-Phe
     254 <220> FEATURE:
     255 <221> NAME/KEY: MISC FEATU E
     256 <222> LOCATION: (7)..(7)
     257 <223> OTHER INFORMATION: i: Thr, GABA, (D) - or (L)-1Nal, (D) - or (L)-2Nal, or (D) - or
{L
     258 .
               )-Phe
     261 <4,00> SEQUENCE: 7
W--> 263 Xaa Xaa Xaa Lys Xaa Xaa Xa
                                                                    see den Son Enov
fuman
Shee
varable legth invalid
     264 1
     267 <210> SEQ ID NO: '8
     268 <211> LENGTH: 9
     269 <212> TYPE: PRT/
C--> 270 <213> ORGANISM( Artificial Feptide
     272 <220> FEATURE:
     273 <221> NAME/KEY: MISC_FEATU F
     274 <222> LOCATION: (1)..(1)
     275 <223> OTHER INFORMATION: i: absent or is a terminal group of one to four amino adds
     278 <220> FEATURE:
     279 <221> NAME/KEY: MISC_FEATCH.
     280 <222> LOCATION: (2)..(2)
     281 <223> OTHER INFORMATION: is 1 Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or
(D
               ) - or (L) - Phe
     282
     285 <220> FEATURE:
     286 <221> NAME/KEY: MISC_FEATURE
     287 <222> LOCATION: (3)..(4)
     288 <223> OTHER INFORMATION: nay be absent, or are independently Gly, Tyr, 1Nal, 2Nal,
Beta-As
                p (Ind), Gly, Tyr, | D) - or (L)-Ala, or (D) - or (L)-Phe
     289
```

Page 6 of 8

DATE: 09/06/2001

```
RAW SEQUENCE LINERING
                                                               TIME: 15:09:42
                     PATENT APPLICATION: US/09/734,583
                     Input Set : A:\\ 7534-0000.txt
                     Output Set: N:\(|X:F3\0:)062001\I734583.raw
    292 <220> FEATURE: .
    293 <221> NAME/KEY: MISC_FEATUR
    294 <222> LOCATION: (5)..(5)
    295 <223> OTHER INFORMATION: (D - cr (L)-Trp
    298 <220> FEATURE:
    299 <221> NAME/KEY: MISC_FEATUR:
    300 <222> LOCATION: (6) .. (6)
    301 <223> OTHER INFORMATION: (D - or (L)-Lys
    304 <220> FEATURE:
    305 <221> NAME/KEY: MISC_FEATUR :
    306 <222> LOCATION: (7)..(7)
    307 <223> OTHER INFORMATION: is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or
(D)
               - or (L)-Phe
     308
     311 <220> FEATURE:
     312 <221> NAME/KEY: MISC_FEATUR :
     313 <222> LOCATION: (8)..(8)
     314 <223> OTHER INFORMATION: i.: (:ys, (D) - or (L) -Ala, or (D) - or (L) -Phe
     317 <220> FEATURE:
     318 <221> NAME/KEY: MISC_FEATULE
     319 <222> LOCATION: (9)..(9)
     320 <223> OTHER INFORMATION: in absent or is Val, Thr, 1Nal or 2Nal
     323 /400> SEQUENCE: 8
W--> 325/Xaa) Xaa Xaa Xaa Xaa Xaa Xaa Kaa Kaa
              r .
                       5
     326 1
     329 ₹210> SEQ ID NO: 9
     330 <211> LENGTH: 7
     331 <212> TYPE: PRT
C--> 332 <213> ORGANISM: (Artificiál Papitile
     334 <220> FEATURE:
     335 <221> NAME/KEY: MISC FEATU E
     337 <223> OTHER INFORMATION: (:)- or (L)-Phe, Tyr or (D)- or (L)-Ala; Residue 1 is
     336 <222> LOCATION: (1)..(1)
                to Residue 7 by a bricge comprised of 1 to 5 methylene spacers (co) Cohnected
connected
     338
               fincected to an amid: thicether, thioester, or disulfide, followe
     339
                d by 1 to 5 methyler a spacers
     343 <220> FEATURE:
     344 <221> NAME/KEY: MISC_FEATURE
     345 <222> LOCATION: \{2\}...\{2\}
                                    0) - or (L)-Phe, Tyr or (D)- or (L)-Ala;
     346 <223> OTHER INFORMATION:
     349 <220> FEATURE:
      350 <221> NAME/KEY: MISC_FEATURE
      351 <222> LOCATION: (3)..(3)
      352 <223> OTHER INFORMATION: 33 absent or is (D) - or (L) -Phe, Tyr or (D) - or (L) -Ala;
      355 <220> FEATURE:
      356 <221> NAME/KEY: MISC_FEATURE
      357 <222> LOCATION: (4)..(4)
      358 <223> OTHER INFORMATION: s (D) or (L) Tyr
      361 <220> FEATURE:
      362 <221> NAME/KEY: MISC_FEAT RE
                                        Use of a and/or Xaa has been detected in the Sequence Listing.
                                        Feniew the Sequence Listing to insure a corresponding
                                       explanation is presented in the <220> to <223> fields of
                                       each sequence using n or X28.
                                                                                               9/6/01
 file://C:\Crf3\Outhold\VsrI734583.htm
```

Page 7 of 8

VERIFICATION SU MARY
PATENT APPLICATION: US/09/734,583

DATE: 09/06/2001
TIME: 15:09:43

Input Set : A:\\:7534-3000.txt

Output Set: N:\ IF3\09062001\1734583.raw

L:30 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:2
L:33 M:257 W: Feature value mis-spel Led or invalid, <221> Name/Key for SEQ ID#:3
L:54 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3
L:88 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:4
L:98 M:257 W: Feature value mis-spel Led or invalid, <221> Name/Key for SEQ ID#:5
L:118 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:5
L:121 M:257 W: Feature value mis-spel Led or invalid, <221> Name/Key for SEQ ID#:5
L:121 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:6
L:212 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:6
L:219 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:7
L:263 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:7
L:270 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:8
L:332 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:8
L:332 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:8
L:338 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:9
L:381 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:9
L:388 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:9
L:388 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:9
L:388 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:10
L:437 M:341 W: (46) "n" or "Xaa" used for SEQ ID#:9
L:388 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:10



SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.
			΄ Γ		EXAMINER
			[	ART UNIT	PAPER NUMBER
			· [	DATE MAN ED:	

Please find below a communication fro who E KAMINER in charge of this application

Commissioner of Patents

1. This application contains so we need disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence elisting was submitted. However, the GRF could not be processed by the Scientific and Texturical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem F.epor. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.8 5) before the application can be examined under 35 U.S.C.

Applicant is given ONE M DINTH from the mailing date of this communication within which to comply with the sequence rules, 17 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANI CNMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtaine they filling a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette: Problem Report with the reply.

nnish Gupta

Aparation No.: 02 734,583
---------------------------

## NOTICE TO COMPLY WITH REQUIRENENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/HIS AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated be ow within the time period set the Office action to which the Notice is attached to avoid about numer under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 3 TOFR 1.136(a)).

The nucleotide and/or amino acid equer ce disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1	attention is directed to the OG 29 (May 15, 1990). If	to non-ply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's rial rule making notice published at 55 FR 18230 (May 1, 1990), and 1114 are differitive filing date is on or after July 1, 1998, see the final rulemaking \$600 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	<b>2.</b>	This application does not a Listing" as required by 37	initain, is a separate part of the disclosure on paper copy, a "Sequence I.F.R. 1 821(c).
		A copy of the "Sequence I 37 C.F.R. 1.821(e).	sling" in computer readable form has not been submitted as required by
		content of the computer it	stin 3" in computer readable form has been submitted. However, the figatile form does not comply with the requirements of 37 C.F.R. 1.822 in the attached copy of the marked -up "Raw Sequence Listing."
X		and/or unreadable as indi-	In that I as been filed with this application has been found to be damaged lifed on the attached CRF Diskette Problem Report. A Substitute ist be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the *S∈ "Sequence Listing" as req	luer ce Listing" is not the same as the computer readable from of the ned by 37 C.F.R. 1.821(e).
_	_		
Ц	7.	Other:	
Ap		Other:cant Must Provide:	
Ap	plic	cant Must Provide:	e neadable form (CRF) copy of the "Sequence Listing".
X	<b>pli</b> c An An	cant Must Provide: n initial or <u>substitute</u> compu n initial or <u>substitute</u> paper to the specification.	e readable form (CRF) copy of the "Sequence Listing".
X	Plic An An int As	cant Must Provide:  In initial or substitute compute initial or substitute paper to the specification.	e readable form (CRF) copy of the "Sequence Listing".
X X X	An An interest An ap 1.8	cant Must Provide: In initial or substitute computed in initial or substitute paper to the specification.  In statement that the content plicable, include no new new 1825(b) or 1.825(d).	to readable form (CRF) copy of the "Sequence Listing".  copy of the "Sequence Listing", as well as an amendment directing its entry  of the paper and computer readable copies are the same and, where
X X For For	An A	cant Must Provide: In Initial or substitute compute in Initial or substitute paper to the specification.  Instatement that the content opticable, include no new notes in 1.825(d).  Instatement that the content opticable, include no new notes include no new notes in the pricable of the content opticable, include no new notes in the content opticable, include no new notes in the content of the c	is madable form (CRF) copy of the "Sequence Listing".  idouglet form (CRF) copy of th

## COUNT SHEET FOR SEQUENCE CASES

Serial No. <u>09/734,583</u>	AE
Mark only one space below	Date of Count
X	(CFIFN) (CRF is unreadable; use CRF Diskette Problem Report)
	(CT (FID)) (CRF does not comply; use Notice to Comply)
·	(CI  FFI) (CRF required but none submitted; use Notice to Comply)
	(bt na fitle) (second or subsequent letter to applicant reporting bona fide attempt to comply; use Notice to Comply and send copy of RSL)
<u> </u>	(no n tiona fide) (second or subsequent letter to applicant reporting non-bona fide attempt to comply; use Notice to Comply and send copy of RSL)

GAU 1653

Examiner Anish Gupta

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:	
☑ BLACK BORDERS	
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES	
☐ FADED TEXT OR DRAWING	
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING	
☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS	
GRAY SCALE DOCUMENTS	
☐ LINES OR MARKS ON ORIGINAL DOCUMENT	
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY	
Потигр.	

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.